
Bibliography
Research using CPRD data has informed drug safety guidance and clinical practice and resulted in over 2,300 peer-reviewed publications.
The CPRD bibliography is updated on a monthly basis (last updated 4 November 2019) and papers are listed below and in the PDF below.
If you have published papers using CPRD data which are not included in this list, please contact us at enquiries@cprd.com so that we can update the bibliography.
Download:
(PDF, 3MB, 192 pages)
“Atypical antipsychotics and hyperglycemic emergencies: multicentre, retrospective cohort study of administrative data”, Schizophr Res, vol. 154, pp. 54-60, 2014.
, “Autism and DPT vaccination in the United Kingdom”, N Engl J Med, vol. 350, pp. 2722-3, 2004.
, “Autoimmune cholestatic liver disease in people with coeliac disease: a population-based study of their association”, Aliment Pharmacol Ther, vol. 21, pp. 401-5, 2005.
, “Autosomal Recessive NRL Mutations in Patients with Enhanced S-Cone Syndrome”, Genes (Basel), vol. 9, 2018.
, , “Bariatric Surgery in the United Kingdom: A Cohort Study of Weight Loss and Clinical Outcomes in Routine Clinical Care”, PLoS Med, vol. 12, p. e1001925, 2015.
, “Basal-bolus Therapy in Patients with Type 2 Diabetes Mellitus in the UK: Patient Characteristics, Treatment Patterns and the Effect of Switching to Premixed Insulin”, Diabetes Ther, vol. 7, pp. 793-807, 2016.
, “Baseline risk of gastrointestinal disorders among new users of meloxicam, ibuprofen, diclofenac, naproxen and indomethacin”, Pharmacoepidemiol Drug Saf, vol. 9, pp. 113-7, 2000.
, “Bell's palsy and parenteral inactivated influenza vaccine”, Hum Vaccin, vol. 2, pp. 110-2, 2006.
, “Benefits and Harms of Antihypertensive Treatment in Low-Risk Patients With Mild Hypertension”, JAMA Intern Med, vol. 178, pp. 1626-1634, 2018.
, “Benefits of combining prevalent and incident cohorts: An application to myotonic dystrophy”, Stat Methods Med Res, p. 962280218804275, 2018.
, “Benign tumors in myotonic dystrophy type I target disease-related cancer sites”, Ann Clin Transl Neurol, vol. 6, pp. 1510-1518, 2019.
, “Benzodiazepine Use and Risk of Developing Alzheimer's Disease or Vascular Dementia: A Case-Control Analysis”, Drug Saf, vol. 38, pp. 909-19, 2015.
, “Benzodiazepines and risk of death: Results from two large cohort studies in France and UK”, Eur Neuropsychopharmacol, vol. 25, pp. 1566-77, 2015.
, “Beta-blocker usage after malignant melanoma diagnosis and survival: a population-based nested case-control study”, Br J Dermatol, vol. 170, pp. 930-8, 2014.
, “Beta-blocker usage and breast cancer survival: a nested case-control study within a UK clinical practice research datalink cohort”, Int J Epidemiol, vol. 42, pp. 1852-61, 2013.
, “beta-Blocker usage and colorectal cancer mortality: a nested case-control study in the UK Clinical Practice Research Datalink cohort”, Ann Oncol, vol. 24, pp. 3100-6, 2013.
, “Bias from depletion of susceptibles: the example of hormone replacement therapy and the risk of venous thromboembolism”, Pharmacoepidemiol Drug Saf, vol. 26, pp. 554-560, 2017.
, “Biochemical monitoring after initiation of aldosterone antagonist therapy in users of renin-angiotensin system blockers: a UK primary care cohort study”, BMJ Open, vol. 7, p. e018153, 2017.
, “Bisphosphonate therapy start may transiently increase the risk of tendon rupture in patients with glucocorticoid co-medication: a population-based observational study”, Pharmacoepidemiol Drug Saf, vol. 25, pp. 1116-1123, 2016.
, “Bisphosphonates and esophageal cancer–a pathway through the confusion”, Nat Rev Rheumatol, vol. 7, pp. 369-72, 2011.
, “Bisphosphonates and risk of upper gastrointestinal cancer–a case control study using the General Practice Research Database (GPRD)”, PLoS One, vol. 7, p. e47616, 2012.
, “Bisphosphonates as potential adjuvants for patients with cancers of the digestive system”, World J Gastroenterol, vol. 22, pp. 906-16, 2016.
, “Bivalent human papillomavirus vaccine and the risk of fatigue syndromes in girls in the UK”, Vaccine, vol. 31, pp. 4961-7, 2013.
, “Bleeding After Hospital Discharge Following Acute Coronary Syndrome: Incidence, Types, Timing, and Predictors”, J Am Heart Assoc, vol. 8, p. e013679, 2019.
, “Blood Eosinophil Counts, Withdrawal of Inhaled Corticosteroids and Risk of COPD Exacerbations and Mortality in the Clinical Practice Research Datalink (CPRD)”, Copd, pp. 1-8, 2019.
, “Blood eosinophilia, use of inhaled corticosteroids, and risk of COPD exacerbations and mortality”, Pharmacoepidemiol Drug Saf, vol. 27, pp. 1191-1199, 2018.
, “Blood Pressure and Risk of Vascular Dementia: Evidence From a Primary Care Registry and a Cohort Study of Transient Ischemic Attack and Stroke”, Stroke, vol. 47, pp. 1429-35, 2016.
, “Blood Pressure Trajectories in the 20 Years Before Death”, JAMA Intern Med, vol. 178, pp. 93-99, 2018.
, “BMI and risk of dementia in two million people over two decades: a retrospective cohort study”, Lancet Diabetes Endocrinol, vol. 3, pp. 431-436, 2015.
, “Body mass index and Hodgkin's lymphoma: UK population-based cohort study of 5.8 million individuals”, Br J Cancer, 2019.
, “Body mass index and the incidence of influenza-associated pneumonia in a UK primary care cohort”, Influenza Other Respir Viruses, vol. 6, pp. 28-36, 2012.
, “Body mass index and use and costs of primary care services among women aged 55-79 years in England: a cohort and linked data study”, Int J Obes (Lond), 2018.
, “Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5.24 million UK adults”, Lancet, vol. 384, pp. 755-65, 2014.
, “Body-mass index and risk of advanced chronic kidney disease: Prospective analyses from a primary care cohort of 1.4 million adults in England”, PLoS One, vol. 12, p. e0173515, 2017.
, “Bone fracture risk is not associated with the use of glucagon-like peptide-1 receptor agonists: a population-based cohort analysis”, Calcif Tissue Int, vol. 97, pp. 104-12, 2015.
, “Bone fractures in children with autistic spectrum disorder”, J Dev Behav Pediatr, vol. 35, pp. 353-9, 2014.
, “Breast cancer incidence and use of antihypertensive medication in women”, Pharmacoepidemiol Drug Saf, vol. 13, pp. 581-5, 2004.
, “Breast cancer risk among users of antidepressant medications”, Epidemiology, vol. 16, pp. 101-5, 2005.
, “Bridging differences in outcomes of pharmacoepidemiological studies: design and first results of the PROTECT project”, Curr Clin Pharmacol, vol. 9, pp. 130-8, 2014.
, “Bronchiectasis and the risk of cardiovascular disease: a population-based study”, Thorax, vol. 72, pp. 161-166, 2017.
, “Budget impact analysis of oral glycopyrronium bromide (Sialanar™) for the symptomatic treatment of severe sialorrhoea (Drooling) in the UK setting”, Value in Health, vol. 20, p. A720, 2017.
, “Burden of Comorbidity in Systemic Lupus Erythematosus in the UK, 1999-2012”, Arthritis Care Res (Hoboken), vol. 68, pp. 819-27, 2016.
, “Burden of herpes zoster in 16 selected immunocompromised populations in England: a cohort study in the Clinical Practice Research Datalink 2000-2012”, BMJ Open, vol. 8, p. e020528, 2018.
, “Burden of Illness in UK Subjects with Reported Respiratory Infections Vaccinated or Unvaccinated against Influenza: A Retrospective Observational Study”, PLoS One, vol. 10, p. e0134928, 2015.
, “Calcium channel blockers and cancer: a risk analysis using the UK Clinical Practice Research Datalink (CPRD)”, BMJ Open, vol. 6, p. e009147, 2016.
, “Calcium-channel blockers and risk of cancer”, Lancet, vol. 349, pp. 1699-700, 1997.
, “Calculating Total Health Service Utilisation and Costs from Routinely Collected Electronic Health Records Using the Example of Patients with Irritable Bowel Syndrome Before and After Their First Gastroenterology Appointment”, Pharmacoeconomics, vol. 34, pp. 181-94, 2016.
, , ,